Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 6/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31043040 | 0.91 | EZH2 (0.37) | DHODHVCPLMNACSF1RADORA2B | |
| SCHEMBL25332134 | 0.91 | EZH2 (0.37) | DHODHVCPLMNACSF1RADORA2B | |
| SCHEMBL1899353 | 0.88 | CSF1R (0.38) | DHODHVCPCSF1RADORA2BDRD2 | |
| SCHEMBL29386984 | 0.82 | CSF1R (0.42) | DHODHVCPCSF1RADORA2BDRD2 | |
| SCHEMBL1897623 | 0.82 | CSF1R (0.42) | DHODHVCPCSF1RADORA2BDRD2 | |
| SCHEMBL27808389 | 0.81 | ADORA2B (0.37) | DHODHVCPLMNAADORA2BDRD2 | |
| SCHEMBL31043039 | 0.80 | CSF1R (0.43) | DHODHVCPCSF1RDRD2DRD4 | |
| SCHEMBL1897985 | 0.80 | CSF1R (0.43) | DHODHVCPCSF1RDRD2DRD4 | |
| SCHEMBL3419133 | 0.79 | EZH2 (0.40) | LMNA | |
| Sulfuric Acid SCHEMBL30014339 | 0.78 | CSF1R (0.39) | DHODHVCPCSF1RADORA2BNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | claimed |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-02-05 | — | — | US | claimed |
| US-8436038-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-05-07 | — | — | US | claimed |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2010-08-05 | — | — | US | claimed |
| EP-2178870-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009025478-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | claimed |
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | disclosed |
| US-9000028-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2015-04-07 | — | — | US | disclosed |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-02-05 | — | — | US | disclosed |
| US-20130237532-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2013-09-12 | — | — | US | disclosed |
| US-8436038-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237532-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, NFATC1 | DHODH 1097/4885VCP 3548/4885LMNA 907/4885 |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, NFATC1 | DHODH 1097/4885VCP 3548/4885LMNA 907/4885 |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | AQP1, EYA3, SF1 | DHODH 2525/4885VCP 2813/4885LMNA 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.